Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
By
Sue Sutter / Email the Author / PharmAsia News Dec. 22, 2011 5:00 AM GMT
India / Word Count: 1186 / Article # 28111222002
Executive Summary
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
$50.00
Buy Now
For $50.00, purchase this 1186-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.